Unicycive Therapeutics, Inc. (UNCY)
Unicycive Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
Unicycive Therapeutics, Inc. (UNCY) is a Biotechnology company based in US with a market capitalization of $158.6M. Free cash flow was negative at -$31.3M. This page tracks UNCY's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 22 employees · IPO Jul 12, 2021
Valuation
Valuation & price
$8.26as of May 17, 2026· -3.5% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
5.25
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$158.6M
Market cap
—
Revenue growth (YoY)
100.0%
Gross margin
-$31.3M
Free cash flow (USD)
-$41.2M
Net debt
Net cash position
2271.7%
Share dilution
1/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2018 → 2025
Free cash flow by year
2018 → 2025
Gross margin by year
2022 → 2023
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last report: 10-Q filed May 12, 2026
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 2, 2026Filing
Earnings Release
- 8-K eventJun 22, 2026Filing
Annual Meeting Results
- FinancingJun 5, 2026Filing
Securities Registration
- 8-K eventJun 5, 2026Filing
ATM Offering Amendment
- Quarterly reportMay 12, 2026Filing
10-Q Filed
- 8-K eventMay 12, 2026Filing
Earnings Release
- 8-K eventApr 6, 2026Filing
Director Resignation
Questions
Frequently asked questions
What is Unicycive Therapeutics, Inc.'s market cap?
Unicycive Therapeutics, Inc. (UNCY) has a market capitalization of $158.6M.
What is UNCY's P/E ratio?
A meaningful P/E ratio is not available for UNCY — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is UNCY's price-to-book (P/B) ratio?
UNCY trades at 5.25 times book value per share.
Are insiders buying UNCY stock?
SEC Form 4 filings show no open-market insider buys at Unicycive Therapeutics, Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.